ReP USP - Resultado da busca

Artigo de periodico
Simulated lymphatic fluid for in-vitro assessment in pharmaceutical development (2022)
Yousef, Malaz ; Park, Chulhun; Le, Tyson S; Bou-Chacra, Nadia Araci ; Davies, Neal M; Löbenberg, Raimar
Source: Dissolutiom Technologies. Unidade: FCF
Subjects: FÁRMACOS, SISTEMA LINFÁTICO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
YOUSEF, Malaz et al. Simulated lymphatic fluid for in-vitro assessment in pharmaceutical development. Dissolutiom Technologies, v. 29, n. 2, p. 86-93, 2022Tradução . . Disponível em: https://doi.org/10.14227/DT290222P86. Acesso em: 03 set. 2024.
APA
Yousef, M., Park, C., Le, T. S., Bou-Chacra, N. A., Davies, N. M., & Löbenberg, R. (2022). Simulated lymphatic fluid for in-vitro assessment in pharmaceutical development. Dissolutiom Technologies, 29( 2), 86-93. doi:10.14227/DT290222P86
NLM
Yousef M, Park C, Le TS, Bou-Chacra NA, Davies NM, Löbenberg R. Simulated lymphatic fluid for in-vitro assessment in pharmaceutical development [Internet]. Dissolutiom Technologies. 2022 ; 29( 2): 86-93.[citado 2024 set. 03 ] Available from: https://doi.org/10.14227/DT290222P86
Vancouver
Yousef M, Park C, Le TS, Bou-Chacra NA, Davies NM, Löbenberg R. Simulated lymphatic fluid for in-vitro assessment in pharmaceutical development [Internet]. Dissolutiom Technologies. 2022 ; 29( 2): 86-93.[citado 2024 set. 03 ] Available from: https://doi.org/10.14227/DT290222P86
Trabalho de evento
In-vitro model to forecast the lymphatic uptake/inhibition of drugs via chylomicrons (2022)
Yousef, Malaz ; Bou-Chacra, Nadia Araci ; Davies, Neal M; Löbenberg, Raimar
Source: Abstracts. Conference titles: Research Day Equity in Health and Research. Unidade: FCF
Subjects: FÁRMACOS, XENOBIÓTICO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
YOUSEF, Malaz et al. In-vitro model to forecast the lymphatic uptake/inhibition of drugs via chylomicrons. 2022, Anais.. Alberta: University of Alberta, 2022. Disponível em: https://www.cspscanada.org/wp-content/uploads/CSPS-2022-Malaz-Yousef.pdf. Acesso em: 03 set. 2024.
APA
Yousef, M., Bou-Chacra, N. A., Davies, N. M., & Löbenberg, R. (2022). In-vitro model to forecast the lymphatic uptake/inhibition of drugs via chylomicrons. In Abstracts. Alberta: University of Alberta. Recuperado de https://www.cspscanada.org/wp-content/uploads/CSPS-2022-Malaz-Yousef.pdf
NLM
Yousef M, Bou-Chacra NA, Davies NM, Löbenberg R. In-vitro model to forecast the lymphatic uptake/inhibition of drugs via chylomicrons [Internet]. Abstracts. 2022 ;[citado 2024 set. 03 ] Available from: https://www.cspscanada.org/wp-content/uploads/CSPS-2022-Malaz-Yousef.pdf
Vancouver
Yousef M, Bou-Chacra NA, Davies NM, Löbenberg R. In-vitro model to forecast the lymphatic uptake/inhibition of drugs via chylomicrons [Internet]. Abstracts. 2022 ;[citado 2024 set. 03 ] Available from: https://www.cspscanada.org/wp-content/uploads/CSPS-2022-Malaz-Yousef.pdf
Artigo de periodico
Biphasic dissolution as an exploratory method during early drug product development (2020)
Silva, Daniela Amaral; Gousous, Jozef Al; Davies, Neal M; Bou-Chacra, Nadia Araci ; Webster, Gregory K; Lipka, Elke; Amidon, Gordon L; Löbenberg, Raimar
Source: Pharmaceutics. Unidade: FCF
Subjects: ANTI-INFLAMATÓRIOS, FÁRMACOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SILVA, Daniela Amaral et al. Biphasic dissolution as an exploratory method during early drug product development. Pharmaceutics, v. 12, p. 1-17 art, 2020Tradução . . Disponível em: https://doi.org/10.3390/pharmaceutics12050420. Acesso em: 03 set. 2024.
APA
Silva, D. A., Gousous, J. A., Davies, N. M., Bou-Chacra, N. A., Webster, G. K., Lipka, E., et al. (2020). Biphasic dissolution as an exploratory method during early drug product development. Pharmaceutics, 12, 1-17 art. doi:10.3390/pharmaceutics12050420
NLM
Silva DA, Gousous JA, Davies NM, Bou-Chacra NA, Webster GK, Lipka E, Amidon GL, Löbenberg R. Biphasic dissolution as an exploratory method during early drug product development [Internet]. Pharmaceutics. 2020 ; 12 1-17 art.[citado 2024 set. 03 ] Available from: https://doi.org/10.3390/pharmaceutics12050420
Vancouver
Silva DA, Gousous JA, Davies NM, Bou-Chacra NA, Webster GK, Lipka E, Amidon GL, Löbenberg R. Biphasic dissolution as an exploratory method during early drug product development [Internet]. Pharmaceutics. 2020 ; 12 1-17 art.[citado 2024 set. 03 ] Available from: https://doi.org/10.3390/pharmaceutics12050420
Artigo de periodico
Mechanistic understanding of underperforming enteric coated products: opportunities to add clinical relevance to the dissolution test (2020)
Silva, Daniela Amaral; Davies, Neal M; Doschak, Michael R; Al-Gousous, Jozef; Bou-Chacra, Nadia Araci ; Löbenberg, Raimar
Source: Journal of Controlled Release. Unidade: FCF
Assunto: FÁRMACOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SILVA, Daniela Amaral et al. Mechanistic understanding of underperforming enteric coated products: opportunities to add clinical relevance to the dissolution test. Journal of Controlled Release, v. 325, p. 23-334, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.jconrel.2020.06.031. Acesso em: 03 set. 2024.
APA
Silva, D. A., Davies, N. M., Doschak, M. R., Al-Gousous, J., Bou-Chacra, N. A., & Löbenberg, R. (2020). Mechanistic understanding of underperforming enteric coated products: opportunities to add clinical relevance to the dissolution test. Journal of Controlled Release, 325, 23-334. doi:10.1016/j.jconrel.2020.06.031
NLM
Silva DA, Davies NM, Doschak MR, Al-Gousous J, Bou-Chacra NA, Löbenberg R. Mechanistic understanding of underperforming enteric coated products: opportunities to add clinical relevance to the dissolution test [Internet]. Journal of Controlled Release. 2020 ; 325 23-334.[citado 2024 set. 03 ] Available from: https://doi.org/10.1016/j.jconrel.2020.06.031
Vancouver
Silva DA, Davies NM, Doschak MR, Al-Gousous J, Bou-Chacra NA, Löbenberg R. Mechanistic understanding of underperforming enteric coated products: opportunities to add clinical relevance to the dissolution test [Internet]. Journal of Controlled Release. 2020 ; 325 23-334.[citado 2024 set. 03 ] Available from: https://doi.org/10.1016/j.jconrel.2020.06.031
Artigo de periodico
Simulated, biorelevant, clinically relevant or physiologically relevant dissolution media: the hidden role of bicarbonate buffer (2019)
Silva, Daniela Amaral; Gousous, Jozef Al; Davies, Neal M; Bou-Chacra, Nadia Araci ; Webster, Gregory K; Lipka, Elke; Amidon, Gordon; Löbenberg, Raimar
Source: European Journal of Pharmaceutics and Biopharmaceutics. Unidade: FCF
Subjects: FÁRMACOS, FORMAS FARMACÊUTICAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SILVA, Daniela Amaral et al. Simulated, biorelevant, clinically relevant or physiologically relevant dissolution media: the hidden role of bicarbonate buffer. European Journal of Pharmaceutics and Biopharmaceutics, v. 142, p. 8-19, 2019Tradução . . Disponível em: https://doi.org/10.1016/j.ejpb.2019.06.006. Acesso em: 03 set. 2024.
APA
Silva, D. A., Gousous, J. A., Davies, N. M., Bou-Chacra, N. A., Webster, G. K., Lipka, E., et al. (2019). Simulated, biorelevant, clinically relevant or physiologically relevant dissolution media: the hidden role of bicarbonate buffer. European Journal of Pharmaceutics and Biopharmaceutics, 142, 8-19. doi:10.1016/j.ejpb.2019.06.006
NLM
Silva DA, Gousous JA, Davies NM, Bou-Chacra NA, Webster GK, Lipka E, Amidon G, Löbenberg R. Simulated, biorelevant, clinically relevant or physiologically relevant dissolution media: the hidden role of bicarbonate buffer [Internet]. European Journal of Pharmaceutics and Biopharmaceutics. 2019 ; 142 8-19.[citado 2024 set. 03 ] Available from: https://doi.org/10.1016/j.ejpb.2019.06.006
Vancouver
Silva DA, Gousous JA, Davies NM, Bou-Chacra NA, Webster GK, Lipka E, Amidon G, Löbenberg R. Simulated, biorelevant, clinically relevant or physiologically relevant dissolution media: the hidden role of bicarbonate buffer [Internet]. European Journal of Pharmaceutics and Biopharmaceutics. 2019 ; 142 8-19.[citado 2024 set. 03 ] Available from: https://doi.org/10.1016/j.ejpb.2019.06.006
Artigo de periodico
Application of in silico tools in clinical practice using Ketoconazole as a model drug (2018)
Silva, Daniela Amaral; Duque, Marcelo Dutra; Davies, Neal M; Löbenberg, Raimar; Ferraz, Humberto Gomes
Source: Journal of Pharmacy and Pharmaceutical Sciences. Unidade: FCF
Subjects: ANTIFÚNGICOS, FÁRMACOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SILVA, Daniela Amaral et al. Application of in silico tools in clinical practice using Ketoconazole as a model drug. Journal of Pharmacy and Pharmaceutical Sciences, v. 21, n. 1s, p. 242s-253s, 2018Tradução . . Disponível em: https://www.ncbi.nlm.nih.gov/pubmed/30348250. Acesso em: 03 set. 2024.
APA
Silva, D. A., Duque, M. D., Davies, N. M., Löbenberg, R., & Ferraz, H. G. (2018). Application of in silico tools in clinical practice using Ketoconazole as a model drug. Journal of Pharmacy and Pharmaceutical Sciences, 21( 1s), 242s-253s. Recuperado de https://www.ncbi.nlm.nih.gov/pubmed/30348250
NLM
Silva DA, Duque MD, Davies NM, Löbenberg R, Ferraz HG. Application of in silico tools in clinical practice using Ketoconazole as a model drug [Internet]. Journal of Pharmacy and Pharmaceutical Sciences. 2018 ; 21( 1s): 242s-253s.[citado 2024 set. 03 ] Available from: https://www.ncbi.nlm.nih.gov/pubmed/30348250
Vancouver
Silva DA, Duque MD, Davies NM, Löbenberg R, Ferraz HG. Application of in silico tools in clinical practice using Ketoconazole as a model drug [Internet]. Journal of Pharmacy and Pharmaceutical Sciences. 2018 ; 21( 1s): 242s-253s.[citado 2024 set. 03 ] Available from: https://www.ncbi.nlm.nih.gov/pubmed/30348250

USP Schools

ReP

Filtros

Authors

Subjects

Source title

Non normalized affiliation